Mucopolysaccharidosis Mps Iii C C0086649
An inherited metabolic disorder that causes progressive damage to the brain and nervous system. Children experience developmental regression, severe behavioral problems, and eventual loss of cognitive abilities. Treatment aims to manage symptoms and provide supportive care.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Developmental delay
(nervous)Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Behavioral problems
(nervous)Hearing loss
(sensory)Recurrent infections
(immune)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and Sleep Management
Structured behavioral interventions addressing the characteristic sleep disturbances, hyperactivity, and behavioral changes in MPS III-c. Environmental modifications and consistent routines are key therapeutic components.
Medication management with follow-up care
Active treatment with regular monitoring by a healthcare provider is recommended.
Seizure and Symptom Control
Anticonvulsant therapy for seizure management and pharmacological support for associated symptoms such as agitation, constipation, and respiratory secretions. Treatment is tailored to individual symptom patterns.
Additional treatment options
Mobility Support and Comfort Care
Physical therapy interventions focused on maintaining comfort, preventing contractures, and supporting safe positioning. Gentle range of motion exercises and specialized seating systems help preserve function.
physical_therapyProgressive Disease Monitoring
Ongoing assessment of neurological decline, functional abilities, and emerging medical complications. Regular reviews of cardiac, respiratory, and nutritional status guide supportive care decisions.
monitoringExperimental Therapy Programs
Enrollment in clinical trials and expanded access programs investigating novel therapies for MPS III-c including substrate reduction, gene therapy, and combination approaches.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Mucopolysaccharidosis Mps Iii C C0086649?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Mucopolysaccharidosis Mps Iii C C0086649. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy